Efficacy and Safety Evaluation of MONOBLUE DUAL View and MONOBLUE ILM View Vital Stains

Universitaire Ziekenhuizen KU Leuven100 enrolled

Overview

In this study, the investigators aim to collect data regarding the efficiency and safety of two dyes used intraoperatively in vitrectomy to stain intraocular tissues. These products have the necessary approvals to use during such operation,These are NOT experimental products.

To determine efficacy and safety of MONOBLUE DUAL View and MONOBLUE ILM View (study products) vital stains during vitrectomy surgery. Both study products are CE-marked and legally marketed in Europe. The data collection will serve as Post-Marketing Clinical Follow-up according MDR provisions. Retrospective data will also be collected for the two reference products: ILM Blue® (DORC) and Membrane Blue Dual® (DORC) to serve as control. For this purpose, patient data will be used that were collected in studies S61408 (Comparative study 23G vs 27G vitrectomy), S63610 (Comparative study 27G vitrectomy vs larger gauge surgery) and S64913 (EVA Nexus Field Observation Study). The expected effect of the study products is to provide the retinal surgeon with adequate aid in visualizing the membranes involved in the retinal pathology to treat, thanks to their staining capabilities. The performance of the study products is related to the visualization of retinal tissues (ILM and/or ERM) during the vitrectomy procedure, when these tissues cannot be distinguished accurately enough without staining. Their use allows for better identification of these tissues and facilitates their removal by the surgeon. The clinical benefit of using ophthalmic dyes is to increase the patient's ability to recover anatomically and functionally by allowing more precise surgery with an effective visualization tool. Along with collecting post-marketing clinical follow-up data on the subject products, the outcomes of the present study results may be used at the UZLeuven Hospital to decide to use Monoblue ILM View and/or Monoblue Dual View as standard-of-care, replacing Membrane Blue Dual and ILM Blue.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Macular Holes Macular Pucker Vitreomacular Traction

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Adult patients who underwent for vitrectomy surgery where ILM and/or ERM removal is required: * Macular holes (ILM staining) * Macular pucker (ILM and ERM staining) * Vitreomacular traction (ILM staining) Exclusion Criteria: * Children aged \<18 years * Vitrectomy for other indication than mentioned in 3.1 * Patients that have concomitant eye disease that may influence the outcome of the surgery, e.g. terminal glaucoma * Patients that did to comply to the postoperative examination visit 6-10 weeks after the surgery

Locations (1)

UZ Leuven

Leuven, Vlaams Brabant, Belgium

Outcomes

Primary Outcomes

visualization of membranes

visualization of membranes stained based on binary subjective evaluation.

Time frame: intraoperative (surgery day)

Secondary Outcomes

surgical help

subjective assessment of surgical help provided by the product

Time frame: intraoperative (surgery day)

adverse events

Rate and severity of potential study-related products adverse events

Time frame: 1 day after surgery

visual acuity

Visual outcome at the last postoperative visit

Time frame: 6 weeks after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.